Bunitrolol is a beta-adrenergic antagonist.[1]
Names | |
---|---|
IUPAC name
2-[3-(tert-Butylamino)-2-hydroxypropoxy]benzonitrile
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C14H20N2O2 | |
Molar mass | 248.326 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Synthesis
edit2-Hydroxybenzonitrile (1) is treated with epichlorohydrin and sodium hydroxide to give the epoxide (2). Addition of tert-butylamine completes the synthesis of bunitrolol.[2]
See also
editReferences
edit- ^ Haddad, S; Poulin, P; Funk, C (2010). "Extrapolating in vitro metabolic interactions to isolated perfused liver: Predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine". Journal of Pharmaceutical Sciences. 99 (10): 4406–26. doi:10.1002/jps.22136. PMID 20310018.
- ^ Herbert Koppe, Albrecht Engelhardt, Karl Zeile, U.S. patent 3,940,489 (1976 to Boehringer Ingelheim Gmbh).